Related Experiment Video
Updated: Nov 4, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.6K
In COVID-19, tocilizumab reduces all-cause mortality at 28 d
Shannon M Fernando1, Bram Rochwerg2
1University of Ottawa, Ottawa, Ontario, Canada (S.M.F.).
Annals of Internal Medicine
|May 31, 2021
Summary
Interleukin-6 (IL-6) blocking agents show potential for treating COVID-19 patients. This living systematic review synthesizes current evidence on their efficacy and safety.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- COVID-19, a severe respiratory illness, is characterized by a cytokine storm.
- Interleukin-6 (IL-6) plays a key role in mediating this inflammatory response.
- Targeting IL-6 is a potential therapeutic strategy for severe COVID-19.
Purpose of the Study:
- To conduct a living systematic review of randomized controlled trials (RCTs) evaluating IL-6 blocking agents for COVID-19.
- To synthesize evidence on the efficacy and safety of IL-6 inhibitors in hospitalized COVID-19 patients.
Main Methods:
- Systematic search of multiple databases for relevant RCTs.
- Inclusion of studies comparing IL-6 blocking agents (e.g., tocilizumab, sarilumab) with placebo or standard care.
- Living systematic review methodology to incorporate new evidence as it emerges.
Main Results:
- Interleukin-6 blocking agents may reduce the risk of mortality in critically ill COVID-19 patients.
- Evidence suggests a potential benefit in reducing the need for mechanical ventilation.
- Safety profiles require ongoing monitoring, with some studies reporting adverse events.
Conclusions:
- IL-6 blocking agents represent a promising therapeutic option for managing severe COVID-19.
- Further research and real-world data are crucial to refine treatment guidelines.
- Living systematic reviews are essential for rapidly evolving research areas like COVID-19 therapeutics.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
01:26COPD: Management Using Bronchodilators and Corticosteroids
511
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
511
01:14Myocarditis III: Medical Management
44
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
44
01:19Antiasthma Drugs: Leukotriene Modifiers
1.4K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.4K
01:17Pericarditis III: Medical Management
80
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
80